Sobi down as 4th-qtr earnings and sales decline

18 February 2021

Shares of Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, were down more than 8 at 151.20 Swedish kronor by late morning today, after it announced its results for the fourth quarter and full-year 2020.

Revenue for the full-year grew 7% to 15,261 million kronor. Adjusted earnings before interest, taxes and amortization (EBITA) were 6,301 million kronor, up 3% resulting in an adjusted EBITA margin of 41% per cent for the full year.

Sobi's fourth quarter adjusted EBITA fell 9% year-on-year to 2.18 billion kronor, while revenues were 4.58 billion kronor, down 6%, slightly above the 4.49 billion kronor mean forecast of analysts, according to Refinitiv data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK